000180222 001__ 180222
000180222 005__ 20240229145610.0
000180222 0247_ $$2doi$$a10.1186/s13195-022-01017-4
000180222 0247_ $$2pmid$$apmid:35624487
000180222 0247_ $$2altmetric$$aaltmetric:129097752
000180222 037__ $$aDKFZ-2022-01173
000180222 041__ $$aEnglish
000180222 082__ $$a610
000180222 1001_ $$0P:(DE-He78)abb10265fc5b7b424eee557e979d490f$$aNguyen, Mai Thi Ngoc$$b0$$eFirst author$$udkfz
000180222 245__ $$aLong-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer's disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies.
000180222 260__ $$aLondon$$bBioMed Central$$c2022
000180222 3367_ $$2DRIVER$$aarticle
000180222 3367_ $$2DataCite$$aOutput Types/Journal article
000180222 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1654601586_19265
000180222 3367_ $$2BibTeX$$aARTICLE
000180222 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180222 3367_ $$00$$2EndNote$$aJournal Article
000180222 500__ $$a#EA:C070#LA:C070#
000180222 520__ $$aNo population-based cohort study investigated a potential inverse association between long-term low-dose acetylsalicylic acid (ASA) use and all-cause dementia and its two most common sub-types Alzheimer's disease (AD) and vascular dementia (VD) so far.Cox regression models with inverse probability of treatment weighting to model the underlying cardiovascular risk were used to assess the associations of low-dose ASA use with all-cause dementia, AD, and VD incidence in community-dwelling older adults from the German ESTHER study (N = 5258) and the UK Biobank (N = 305,394). Inclusion criteria were age of 55 years or older and completed drug assessment. Meta-analyses of the individual participant data from the two prospective cohort studies were performed.Four hundred seventy-six cases of all-cause dementia, 157 cases of AD, and 183 cases of VD were diagnosed over a median of 14.3 years of follow-up in ESTHER. In the UK Biobank, 5584 participants were diagnosed with all-cause dementia, 2029 with AD, and 1437 with VD over a median of 11.6 years. The meta-analysis of both cohorts revealed a weak reduction in hazards for all-cause dementia (hazard ratio (HR) [95% confidence interval (CI)]: 0.96 [0.93 to 0.99]). The strongest protective effect of low-dose ASA was observed in participants with coronary heart disease (CHD) in both cohorts, and a significant interaction was detected. In particular, in meta-analysis, a 31% reduction in hazard for AD, 69% for VD and 34% for all-cause dementia were observed (HR [95% CI]: 0.69 [0.59 to 0.80], 0.31 [0.27 to 0.35], 0.46 [0.42 to 0.50], respectively). Furthermore, compared to non-users, users of low-dose ASA for 10 years or longer (who likely use it because they have CHD or a related diagnosis putting them at an increased risk for cardiovascular events) demonstrated a strong protective effect on all dementia outcomes, especially for VD (HR [95% CI]: 0.48 [0.42 to 0.56]) whereas no protective associations were observed with shorter low-dose ASA use.The protective potential of low-dose ASA for all-cause dementia, AD, and VD seems to strongly depend on pre-existing CHD and the willingness of patients to take it for a minimum of ten years.
000180222 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000180222 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180222 650_7 $$2Other$$aAcetylsalicylic acid
000180222 650_7 $$2Other$$aAlzheimer’s disease
000180222 650_7 $$2Other$$aAspirin
000180222 650_7 $$2Other$$aCohort study
000180222 650_7 $$2Other$$aCoronary heart disease
000180222 650_7 $$2Other$$aDementia
000180222 650_7 $$2Other$$aMeta-analysis
000180222 650_7 $$2Other$$aPrevention
000180222 650_2 $$2MeSH$$aAged
000180222 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000180222 650_2 $$2MeSH$$aCohort Studies
000180222 650_2 $$2MeSH$$aCoronary Disease: complications
000180222 650_2 $$2MeSH$$aDementia, Vascular: complications
000180222 650_2 $$2MeSH$$aHumans
000180222 650_2 $$2MeSH$$aMiddle Aged
000180222 650_2 $$2MeSH$$aProspective Studies
000180222 650_2 $$2MeSH$$aRisk Factors
000180222 7001_ $$0P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe$$aChen, Li-Ju$$b1$$udkfz
000180222 7001_ $$0P:(DE-He78)b09508a4c4afe85c57dd131eefa689ea$$aTrares, Kira$$b2$$udkfz
000180222 7001_ $$0P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aStocker, Hannah$$b3$$udkfz
000180222 7001_ $$aHolleczek, Bernd$$b4
000180222 7001_ $$aBeyreuther, Konrad$$b5
000180222 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b6$$udkfz
000180222 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b7$$eLast author$$udkfz
000180222 773__ $$0PERI:(DE-600)2506521-X$$a10.1186/s13195-022-01017-4$$gVol. 14, no. 1, p. 75$$n1$$p75$$tAlzheimer's research & therapy$$v14$$x1758-9193$$y2022
000180222 909CO $$ooai:inrepo02.dkfz.de:180222$$pVDB
000180222 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)abb10265fc5b7b424eee557e979d490f$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000180222 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000180222 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b09508a4c4afe85c57dd131eefa689ea$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000180222 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000180222 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000180222 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000180222 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000180222 9141_ $$y2022
000180222 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000180222 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000180222 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000180222 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000180222 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000180222 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS RES THER : 2021$$d2022-11-08
000180222 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000180222 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000180222 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:18:57Z
000180222 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:18:57Z
000180222 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2021-02-14T16:18:57Z
000180222 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-08
000180222 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-08
000180222 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000180222 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000180222 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000180222 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALZHEIMERS RES THER : 2021$$d2022-11-08
000180222 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000180222 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000180222 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000180222 980__ $$ajournal
000180222 980__ $$aVDB
000180222 980__ $$aI:(DE-He78)C070-20160331
000180222 980__ $$aUNRESTRICTED